Revive Therapeutics CSE: RVV | OTC: RVVTF Revive Therapeutics is focused on the R&D and sale of cannabinoid-based products, recently expanding into the psychedelics industry more broadly. Revive Therapeutics$0.36519.67%$0.06 Latest News Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study December 31, 2020 Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access December 23, 2020 Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program December 21, 2020 Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor December 2, 2020 Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics November 18, 2020 Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin November 11, 2020 Join our Newsletter Get the latest Company updates delivered to straight to your inbox. Leave this field empty if you're human: